Company Filing History:
Years Active: 2016-2024
Title: Innovations of Nicholas John Palmer
Introduction
Nicholas John Palmer is a notable inventor based in Cheshire, GB. He has made significant contributions to the field of pharmaceuticals, holding a total of 15 patents. His work primarily focuses on developing compounds that have therapeutic applications.
Latest Patents
Among his latest patents are certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides, which serve as dipeptidyl peptidase 1 inhibitors. These compounds are designed to inhibit dipeptidyl peptidase 1 (DPP1) activity, which is crucial in treating and preventing clinical conditions such as respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD). The patents also cover their utility in therapy, pharmaceutical compositions containing them, and processes for preparing such compounds.
Career Highlights
Nicholas John Palmer is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to contribute to innovative solutions in healthcare, particularly in the development of new therapeutic agents.
Collaborations
He has collaborated with notable colleagues, including Stephen Connolly and Steven Swallow, to advance research and development in his field.
Conclusion
Nicholas John Palmer's contributions to pharmaceutical innovations and his extensive patent portfolio highlight his role as a significant inventor in the industry. His work continues to impact the treatment of respiratory diseases and showcases the importance of innovation in healthcare.